Articles

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Otezla Phase 3 ADVANCE Trial Reports Improvement in Plaque Psoriasis Severity

Nemolizumab shows positive results according to a recently published post hoc analysis of a phase 2b trial evaluating the drug vs placebo in adult patients with moderate to severe atopic dermatitis (AD). 

Nemolizumab Demonstrates Significant Improvement of AD Symptoms in Phase 2b Trial

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.

Malignancy Risk Low in Secukinumab Treatment

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Study Confirms Safety Profile of Baricitinib Dose for Atopic Dermatitis

Timber Pharmaceuticals's phase 2b trial of isotretinoin for congenital ichthyosis (CI) has reached 50% enrollment.

Phase 2b Trial of Topical Isotretinoin for CI Reaches 50% Enrollment

Eli Lilly and Incyte announce results from its phase 3 study evaluating baricitinib 2 mg and 4 mg for the treatment of alopecia areata, making it the first Phase 3 study with top-line results in patients with the hair disorder.

Baricitinib Shows Hair Regrowth in Phase 3 Study for AA

AbbVie announces the submission of regulatory filings for risankizumab to the FDA and EMA seeking approval for the drug as a treatment for psoriatic arthritis.

Drug Watch